QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
LON:IMM

ImmuPharma - IMM Share Forecast, Price & News

GBX 2.17
-0.17 (-7.25%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
2.15
▼
2.30
50-Day Range
2.16
▼
3.79
52-Week Range
2.10
▼
9.50
Volume
219,856 shs
Average Volume
1.68 million shs
Market Capitalization
£7.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMM stock logo

About ImmuPharma (LON:IMM) Stock

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

IMM Stock News Headlines

November 11, 2022 | proactiveinvestors.com
Immupharma’s US partner confirms support for lupus treatment and wants to expand collaboration
November 11, 2022 | proactiveinvestors.com
Immupharma’s US partner confirms support for lupus treatment, wants to expand collaboration
October 13, 2022 | finance.yahoo.com
After losing 57% in the past year, ImmuPharma plc (LON:IMM) institutional owners must be relieved by the recent gain
October 6, 2022 | morningstar.co.uk
TRADING UPDATES: ImmuPharma loss narrows; MetalNRG... - Morningstar
October 6, 2022 | finance.yahoo.com
ImmuPharma plc (IMM.L)
September 30, 2022 | proactiveinvestors.com
ImmuPharma said it welcomes 'helpful' FDA recommendations ahead of phase III study - Proactive Investors USA
September 30, 2022 | proactiveinvestors.com
ImmuPharma says it welcomes 'helpful' FDA recommendations ahead of phase III study - Proactive Investors USA
September 14, 2022 | proactiveinvestors.com
US markets end a roller coaster session in positive territory - Proactive Investors USA
September 14, 2022 | proactiveinvestors.com
US stocks push higher after yesterday's plunge - Proactive Investors USA
September 14, 2022 | proactiveinvestors.com
ImmuPharma says its US partner for Lupuzor has received a written response from the US FDA to its Type C meeting - Proactive Investors USA
September 14, 2022 | marketwatch.com
ImmuPharma Shares Fall on FDA's Lupuzor Treatment Response - MarketWatch
September 7, 2022 | lse.co.uk
PM Truss tells Biden UK will work with U.S. to tackle economic problems | Financial News - London South East
September 7, 2022 | lse.co.uk
ImmuPharma raises GBP150,000 via issue of 3 million new shares | Financial News - London South East
September 1, 2022 | morningstar.co.uk
IN BRIEF: Aferian partners with Swisscom, launches new TV offering - Morningstar
September 1, 2022 | morningstar.co.uk
TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit - Morningstar
August 24, 2022 | marketwatch.com
Systemic Lupus Erythematous SLE Drug Market Is Anticipated to Expand With a CAGR of 4.7% From 2022 to 2028 | 97 Report Pages
August 24, 2022 | reuters.com
IMM.L - ImmuPharma PLC | Stock Price & Latest News | Reuters
August 11, 2022 | morningstar.co.uk
IN BRIEF: ImmuPharma raises GBP950,000 from broker option - Morningstar
August 4, 2022 | proactiveinvestors.com
ImmuPharma raising £1.1mln to aid its R&D effort - Proactive Investors USA
August 3, 2022 | marketwatch.com
ImmuPharma to Raise Up to GBP2.4 Mln; Funds to Be Used Toward R&D Pipeline - MarketWatch
July 13, 2022 | proactiveinvestors.com
ImmuPharma: Equity analyst eyes key FDA decision in August - Proactive Investors USA
July 13, 2022 | proactiveinvestors.com
Genenta Science on track and well financed to begin phase II trial in 2023 - Proactive Investors USA
July 13, 2022 | lse.co.uk
Sylvania Pl News Headlines. SLP Share News. Financial News Articles for Sylvania Platinum Limited Cmn Shs Usd0.01 (Di) updated throughout the day. - London South East
July 7, 2022 | marketwatch.com
ImmuPharma Shares Rise on Formal Meeting Confirmation With FDA Over Lupuzor
June 27, 2022 | proactiveinvestors.com
ImmuPharma PLC partner makes final preparations for phase III trial
See More Headlines
Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

IMM Company Calendar

Last Earnings
9/30/2020
Today
12/06/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:IMM
CUSIP
N/A
CIK
N/A
Web
www.immupharma.org
Phone
+44-20-71524080
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.49
Quick Ratio
1.03

Sales & Book Value

Annual Sales
£94,819.00
Price / Sales
76.48
Cash Flow
GBX 0.09 per share
Price / Cash Flow
23.54
Book Value
GBX 0.70 per share
Price / Book
3.11

Miscellaneous

Outstanding Shares
333,403,000
Free Float
N/A
Market Cap
£7.25 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Timothy Paul McCarthy XIV (Age 65)
    FCCA, M.B.A., MBA, Chairman & CEO
    Comp: $574.67k
  • Dr. Timothy Gary Franklin M.B.A.
    Ph.D., COO & Director
  • Ms. Lisa Baderoon
    Head of Investor Relations & Non Exec. Director
  • Dr. Jean-Marie Geiger PharmD
    MD, Head of Clinical Devel.
  • Dr. Laura Mauran-Ambrosino
    Chief Scientific Officer of ImmuPharma Biotech
  • Dr. Sébastien R. Goudreau Ph.D.
    Chief Exec. Officer of ImmuPharma Biotec

Key Competitors

View All Competitors













IMM Stock - Frequently Asked Questions

How have IMM shares performed in 2022?

ImmuPharma's stock was trading at GBX 6.60 at the beginning of 2022. Since then, IMM stock has decreased by 67.0% and is now trading at GBX 2.18.
View the best growth stocks for 2022 here.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Mining (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

How do I buy shares of ImmuPharma?

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ImmuPharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 2.18.

How much money does ImmuPharma make?

ImmuPharma (LON:IMM) has a market capitalization of £7.25 million and generates £94,819.00 in revenue each year.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The official website for the company is www.immupharma.org. The company can be reached via phone at +44-20-71524080.

This page (LON:IMM) was last updated on 12/6/2022 by MarketBeat.com Staff